Curis | CRIS - Cash And Equivalent


Curis reported $10.14M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Amgen USD 13.99B 1.95B Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
CSL USD 2.16B 633M Jun/2025
Curis USD 10.14M 10.14M Jun/2025
Eli Lilly USD 8.95B 3.67B Jun/2026
Exelixis USD 281.45M 55.3M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026
Verastem USD 181.68M 23.31M Mar/2026